Application of Accutas Hydrogel Technology for Gonorrhoea Diagnosis and No/Go Decision for Ciprofloxacin Use at Point of Care

Accutas 水凝胶技术在淋病诊断中的应用以及护理点环丙沙星使用否/继续决策

• 批准号: 484613-2015
• 负责人: Dillon, JoAnne
• 金额: $ 1.82万
• 依托单位: University of Saskatchewan
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=584429
• 关键词: Application; Accutas; Hydrogel; Technology; Gonorrhoea

The "Accutas" technology developed by Aquila Diagnostic Systems Inc., Edmonton is a rapid point-of-care hydrogel-based diagnostic platform that has earlier successfully detected blood-borne infectious diseases such as malaria and bovine/porcine pathogens. The company is now contemplating its use in detecting antibiotic resistant sexually transmitted infections (STIs e.g. N. gonorrhoeae) which will be revolutionary, given the emergence of many multidrug/totally drug resistant bacteria in recent times. However, the company is faced with some key challenges that include: 1) No scientific expertise in the field of STIs; 2) No access to diagnostic biomarkers of N. gonorrhoeae and its susceptibility to antibiotic (e.g. ciprofloxacin) or expertise to discover the same; 3) No prior experience of developing a diagnostic test using urine/cervical swab samples and for detecting antibiotic resistance. The proposed project aims to solve these problems by developing a diagnostic technique for detecting N. gonorrhoeae and ciprofloxacin resistance from clinical samples that will be compatible with Accutas hydrogel-based technology. This technique is based on Polymerase Chain Reaction (PCR)-based amplification/identification of specific genetic markers of N. gonorrhoeae and resistance. This will involve use of novel probes indigenously developed in the applicant's lab and standardization experiments to ensure high level of specificity and sensitivity. Further, the standardized technique will be incorporated in the "Accutas" test device followed by more refinements and validation test runs. The company will benefit immensely by this research alliance with the applicant, Prof Jo-Anne Dillon who is known for her work in the area of STIs and antibiotic resistance. In very near future, we envisage an effective test for N. gonorrhoeae treatment that would stop transmission at the point of care and facilitate reduced health costs with the prudent use of antimicrobial agents.

由埃德蒙顿的Aquila诊断系统公司开发的“Acutas”技术是一种快速护理点 基于水凝胶的诊断平台，早些时候曾成功检测到 疟疾和牛/猪的病原体。该公司目前正在考虑将其用于检测抗生素 抗药性性传播感染(性传播感染，如淋病)，这将是革命性的，因为 最近出现了许多多重耐药/完全耐药细菌。然而，该公司面临着 面临的一些关键挑战包括：1)没有性传播感染领域的科学专门知识；2)无法获得诊断 淋球菌的生物标志物及其对抗生素(如环丙沙星)的敏感性或发现 相同；3)没有使用尿液/宫颈拭子样本开发诊断测试的先前经验，以及 检测抗生素耐药性。拟议的项目旨在通过开发一种诊断程序来解决这些问题 将从临床样本中检测淋球菌和环丙沙星耐药性的技术 兼容阿卡特拉斯水凝胶技术。这项技术是基于聚合酶链式反应 基于聚合酶链式反应的淋球菌及其耐药性特异遗传标记的扩增/鉴定。这 将涉及使用申请人实验室自主开发的新型探针和标准化实验 以确保高水平的特异性和敏感性。此外，标准化技术将被纳入 “阿卡特拉斯”测试设备随后进行了更多的改进和验证测试。公司将从中受益 通过与申请者Jo-Anne Dillon教授的研究联盟，Jo-Anne Dillon教授以她在 性传播感染和抗生素耐药性的区域。在不久的将来，我们设想对淋病奈瑟菌进行有效的检测。 治疗将阻止在护理点传播，并促进降低医疗成本与审慎的 使用抗菌剂。